🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise worldwide, with data suggesting more than 82 million instances each year. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options currently available.”

Health officials are deeply concerned about the surge in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance found that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This approval represents a significant shift in the therapy of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Results and Global Access

According to findings released by a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which involves a dual-drug approach. The study involved hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Clinicians directly involved have voiced hope. The availability of a one-pill regimen like this is described as a "game-changer" for managing the epidemic. This is considered essential to alleviate the strain of the infection for individuals and to prevent the spread of highly drug-resistant gonorrhoea worldwide.